MedCap AB (STU:61MA) Cyclically Adjusted Revenue per Share: €8.46 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:61MA MedCap AB STU:61MA
95 GF Score
Price €47.06
GF Value €51.52
Valuation Fairly Valued
View Full Analysis

What is MedCap AB Cyclically Adjusted Revenue per Share?

MedCap AB STU:61MA +0.69% 95 Cyclically Adjusted Revenue per Share is €8.46 as of Jun. 2026. GuruFocus rates STU:61MA with a GF Score™ of 95/100 and a GF Value™ of €51.52 (Fairly Valued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MedCap AB's adjusted revenue per share for the three months ended in Jun. 2026 was €3.719. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €8.46 for the trailing ten years ended in Jun. 2026.

During the past 12 months, MedCap AB's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MedCap AB was 13.60% per year. The lowest was 7.60% per year. And the median was 11.50% per year.

As of today (2026-09-22), MedCap AB's current stock price is €47.06. MedCap AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €8.46. MedCap AB's Cyclically Adjusted PS Ratio of today is 5.56.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedCap AB was 7.64. The lowest was 1.62. And the median was 3.63.


MedCap AB  (STU:61MA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MedCap AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=47.06/8.46
=5.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedCap AB was 7.64. The lowest was 1.62. And the median was 3.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MedCap AB Cyclically Adjusted Revenue per Share Related Terms


MedCap AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MedCap AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB Cyclically Adjusted Revenue per Share Chart

MedCap AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 8.03 8.38 8.39 8.46

STU:61MA vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, MedCap AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MedCap AB's Cyclically Adjusted PS Ratio falls into.


STU:61MA
95GF Score
MedCap AB STU:61MA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MedCap AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.719/134.6100*134.6100
=3.719

Current CPI (Jun. 2026) = 134.6100.

MedCap AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201510 1.581 100.301 2.122
201601 1.602 99.931 2.158
201604 1.894 100.732 2.531
201607 1.898 101.080 2.528
201610 1.728 101.485 2.292
201701 1.569 101.326 2.084
201803 1.364 103.962 1.766
201806 1.249 104.875 1.603
201809 1.184 105.679 1.508
201812 1.352 105.912 1.718
201903 1.426 105.886 1.813
201906 1.306 106.742 1.647
201909 1.115 107.214 1.400
201912 1.474 107.766 1.841
202003 1.433 106.563 1.810
202006 1.367 107.498 1.712
202009 1.143 107.635 1.429
202012 1.494 108.296 1.857
202103 1.486 108.360 1.846
202106 1.555 108.928 1.922
202109 1.340 110.338 1.635
202112 1.719 112.486 2.057
202203 1.694 114.825 1.986
202206 1.831 118.384 2.082
202209 1.535 122.296 1.690
202212 1.993 126.365 2.123
202303 2.290 127.042 2.426
202306 2.265 129.407 2.356
202309 2.085 130.224 2.155
202312 2.677 131.912 2.732
202403 2.746 132.205 2.796
202406 2.662 132.716 2.700
202409 2.412 132.304 2.454
202412 2.775 132.987 2.809
202503 2.929 132.825 2.968
202506 3.168 133.699 3.190
202509 3.006 133.480 3.031
202512 3.598 133.380 3.631
202603 3.465 133.550 3.493
202606 3.719 134.610 3.719

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €8.46 mean?
MedCap AB (STU:61MA) has a Cyclically Adjusted Revenue per Share of €8.46 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedCap AB and its competitors.
Is MedCap AB's Cyclically Adjusted Revenue per Share too high?
MedCap AB's current Cyclically Adjusted Revenue per Share is €8.46. Overall, MedCap AB has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
MedCap AB's Cyclically Adjusted Revenue per Share of €8.46 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedCap AB and its competitors. MedCap AB's current Cyclically Adjusted Revenue per Share is €8.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (STU:61MA) is currently considered Fairly Valued. The stock's GF Value™ is €51.52, compared to a current price of €47.06 — trading 8.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €8.46. MedCap AB's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MedCap AB (STU:61MA), the current Cyclically Adjusted Revenue per Share is €8.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (STU:61MA) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of €47.06 is trading 8.7% below its estimated GF Value™ of €51.52. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for STU:61MA:

  • Cyclically Adjusted Revenue per Share: €8.46
  • GF Value™: €51.52 vs. price of €47.06 (8.7% below fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the STU:61MA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedCap AB Business Description

Other Exchanges MCAP:SwedenMCAPs:UK
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
95GF Score

Get the complete analysis for STU:61MA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.06
Price
€51.52
GF Value